Neurocrine to Acquire Soleno Therapeutics in $2.9 Billion All-Cash Deal
AI-generated from multiple sources. Verify before acting on this reporting.
SAN FRANCISCO — Soleno Therapeutics Inc. shares surged Monday after Neurocrine Biosciences Inc. announced an agreement to acquire the biotechnology firm in an all-cash transaction valued at approximately $2.9 billion. The deal, finalized on April 7, 2026, marks a significant consolidation in the rare-disease sector as Neurocrine seeks to expand its therapeutic portfolio through Soleno’s lead asset, VYKAT XR.
Under the terms of the agreement, Neurocrine will pay $46 per share in cash for Soleno, representing a premium over the company’s closing price prior to the announcement. Soleno’s stock climbed sharply in early trading, reflecting investor confidence in the acquisition price and the strategic value of the target’s pipeline. The transaction is expected to close later in 2026, subject to regulatory approval and shareholder consent.
Neurocrine, based in San Diego, has increasingly focused on rare neurological and metabolic disorders in recent years. The acquisition of Soleno, headquartered in South San Francisco, aligns with that strategy by adding VYKAT XR, an extended-release formulation of the drug vykat, to Neurocrine’s pipeline. VYKAT XR is currently under development for the treatment of a rare genetic condition affecting the central nervous system. Industry analysts note that the deal underscores a broader shift in biotech dealmaking toward companies with late-stage assets in underserved therapeutic areas.
Soleno’s board unanimously approved the transaction, citing the immediate liquidity for shareholders and the opportunity to accelerate development of its drug candidates through Neurocrine’s commercial infrastructure. Neurocrine’s leadership stated that the acquisition strengthens its position in rare disease markets and complements its existing pipeline of neurological treatments. The combined entity aims to leverage Neurocrine’s global sales network to bring VYKAT XR to market more rapidly than Soleno could independently.
The deal comes amid heightened activity in the biotechnology sector, where larger pharmaceutical companies are seeking to bolster their rare-disease portfolios through acquisitions. Neurocrine has made several strategic investments in recent years, but this remains its largest transaction to date. Soleno, which has raised capital through multiple funding rounds, will see its independent operations cease upon closing.
Regulatory review is expected to begin in the coming weeks, with the Federal Trade Commission and other agencies likely to assess the competitive impact of the merger. Shareholders of both companies will vote on the transaction, and the deal could face scrutiny if regulators determine it reduces competition in specific rare-disease markets. No timeline has been provided for the completion of regulatory reviews.
Questions remain regarding the integration of Soleno’s research teams and the potential for future collaborations between the two companies. Neurocrine has not disclosed plans for retaining Soleno’s management or the fate of its other pipeline candidates beyond VYKAT XR. The outcome of regulatory proceedings will determine the final structure and timing of the acquisition.